Trevena Inc. (NASDAQ:TRVN)’s share price fell 1.9% during trading on Wednesday . The stock traded as low as $6.77 and last traded at $6.88, with a volume of 121,253 shares trading hands. The stock had previously closed at $7.01.

Several brokerages have recently commented on TRVN. Cowen and Company restated a “buy” rating on shares of Trevena in a research note on Thursday, June 2nd. Zacks Investment Research lowered Trevena from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Brean Capital set a $14.00 price target on Trevena and gave the company a “buy” rating in a research note on Thursday, September 15th. Jefferies Group restated a “buy” rating on shares of Trevena in a research note on Friday, August 5th. Finally, FBR & Co restated a “buy” rating and set a $13.00 price target on shares of Trevena in a research note on Thursday, August 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $14.30.

The firm has a 50 day moving average price of $6.96 and a 200 day moving average price of $7.28. The firm’s market cap is $367.33 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/trevena-inc-trvn-trading-down-1-9.html

Trevena (NASDAQ:TRVN) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by $0.01. Trevena had a negative net margin of 841.00% and a negative return on equity of 45.01%. Equities research analysts forecast that Trevena Inc. will post ($1.55) EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. FMR LLC raised its stake in Trevena by 2.2% in the second quarter. FMR LLC now owns 7,753,948 shares of the biopharmaceutical company’s stock worth $48,850,000 after buying an additional 168,765 shares in the last quarter. Wellington Management Group LLP increased its position in Trevena by 47.0% in the first quarter. Wellington Management Group LLP now owns 5,714,773 shares of the biopharmaceutical company’s stock worth $47,262,000 after buying an additional 1,827,970 shares during the last quarter. BlackRock Fund Advisors increased its position in Trevena by 23.6% in the second quarter. BlackRock Fund Advisors now owns 1,834,099 shares of the biopharmaceutical company’s stock worth $11,555,000 after buying an additional 350,089 shares during the last quarter. Vanguard Group Inc. increased its position in Trevena by 12.5% in the second quarter. Vanguard Group Inc. now owns 1,381,542 shares of the biopharmaceutical company’s stock worth $8,703,000 after buying an additional 153,378 shares during the last quarter. Finally, Vivo Capital LLC acquired a new position in Trevena during the first quarter worth approximately $9,924,000. 75.43% of the stock is currently owned by institutional investors.

About Trevena

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.